Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company....
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company....
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading...